Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment
Etalanetug (E2814) 在显性遗传性阿尔茨海默病中的应用：一项开放标签的 1b/2 期研究，旨在评估其在轻度至中度认知障碍患者中的安全性和靶点结合情况。
期刊:Alzheimers Research & Therapy
影响因子:
doi:10.1186/s13195-026-02047-y
Andreozzi, Erica; Yagi, Takuya; Wildsmith, Kristin; Rawal, Sumit; Horie, Kanta; Boyd, Peter; Takahashi, Eri; Barthélemy, Nicolas R; Aluri, Jagadeesh; Charil, Arnaud; Reilhac, Anthonin; Gordon, Brian A; Flores, Shaney; Verbel, David; Sauter, Nicholas; Benzinger, Tammie L S; McDade, Eric; Mummery, Catherine; Zhou, Jin; Bateman, Randall J; Reyderman, Larisa
